Skip to main content
. 2022 Sep 6;17(9):e0271689. doi: 10.1371/journal.pone.0271689

Fig 6. Lung tissue and serum levels of IL-17 are suppressed following abatacept treatment and negatively correlated with blood Breg and Treg levels.

Fig 6

(A) Lung tissue gene expression level of IL-17 following treatment with the abatacept IN and IP. (B-D) Correlation between percentage of IL-135+IL-10+ producing Bregs, LAG3+ cTregs, or LAG3+ uTregs in the lung and lung level of IL-17. (E) Serum level of IL-17 following treatment with the abatacept IN or IP. (F-H) Correlation between percentage of IL-135+IL-10+ producing Bregs, LAG3+ cTregs, or LAG3+ uTregs in the lung and serum level of IL-17. Lung tissues of 5 mice and PBMCs of 10 mice were used. Statistical test; Pearson’s correlation coefficient with a one‐sided test for significance (P<0.05 significant).